| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/ARCHNEUR.58.1.65 |
| P698 | PubMed publication ID | 11176938 |
| P50 | author | Nicola De Stefano | Q56811273 |
| P2093 | author name string | Matthews PM | |
| Arnold DL | |||
| Antel JP | |||
| Francis GS | |||
| Narayanan S | |||
| Arnaoutelis R | |||
| Tartaglia MC | |||
| P433 | issue | 1 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| disability | Q12131 | ||
| P304 | page(s) | 65-70 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Archives of Neurology | Q15766672 |
| P1476 | title | Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability | |
| P478 | volume | 58 |
| Q42847184 | A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. |
| Q38237032 | A unified cell biological perspective on axon-myelin injury |
| Q92640062 | Aberrant DNA methylation profile exacerbates inflammation and neurodegeneration in multiple sclerosis patients |
| Q36227413 | Acute metabolic brain changes following traumatic brain injury and their relevance to clinical severity and outcome |
| Q30679381 | Adaptive functional changes in the cerebral cortex of patients with nondisabling multiple sclerosis correlate with the extent of brain structural damage |
| Q33907522 | Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis |
| Q35836853 | Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial |
| Q54225482 | An Assay that Predicts In Vivo Efficacy for DNA Aptamers that Stimulate Remyelination in a Mouse Model of Multiple Sclerosis. |
| Q21135504 | Association of retinal and macular damage with brain atrophy in multiple sclerosis |
| Q36878427 | Astrocytes--friends or foes in multiple sclerosis? |
| Q36657652 | Autoimmune modulation of astrocyte-mediated homeostasis. |
| Q33414966 | Axial diffusivity is the primary correlate of axonal injury in the experimental autoimmune encephalomyelitis spinal cord: a quantitative pixelwise analysis |
| Q35126104 | Axonal damage in multiple sclerosis. |
| Q44028578 | Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. |
| Q37014844 | Axonal injury detected by in vivo diffusion tensor imaging correlates with neurological disability in a mouse model of multiple sclerosis. |
| Q35105813 | Axonal injury in multiple sclerosis |
| Q35994386 | Biological markers in CSF and blood for axonal degeneration in multiple sclerosis |
| Q35513272 | Blood pressure normalization post-jugular venous balloon angioplasty |
| Q36135627 | Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study |
| Q31027249 | Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker |
| Q48488406 | Brain atrophy in radiologically isolated syndromes |
| Q37613091 | Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus |
| Q42027997 | Central nervous system remyelination in culture--a tool for multiple sclerosis research |
| Q38782456 | Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis |
| Q92255004 | Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies |
| Q98952041 | Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients |
| Q64911346 | Characterizing Fatigue-Related White Matter Changes in MS: A Proton Magnetic Resonance Spectroscopy Study. |
| Q30764446 | Clinical proton MR spectroscopy in central nervous system disorders |
| Q34590775 | Clinical trials and clinical practice in multiple sclerosis: conventional and emerging magnetic resonance imaging technologies. |
| Q46912034 | Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox? |
| Q47124802 | Cognitive impairment in clinically isolated syndrome: A systematic review |
| Q47135520 | Cognitive impairment in patients with clinically isolated syndrome. |
| Q24672050 | Cognitive impairment in probable multiple sclerosis |
| Q48191058 | Compensatory cortical activation observed by fMRI during a cognitive task at the earliest stage of MS. |
| Q34221185 | Correlation of diffusion and metabolic alterations in different clinical forms of multiple sclerosis |
| Q57403102 | CorticalN-acetyl aspartate is a predictor of long-term clinical disability in multiple sclerosis |
| Q38018550 | Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases. |
| Q48187778 | Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS. |
| Q37432950 | Decreased NAA in gray matter is correlated with decreased availability of acetate in white matter in postmortem multiple sclerosis cortex |
| Q48824529 | Degeneration of corpus callosum and recovery of motor function after stroke: a multimodal magnetic resonance imaging study. |
| Q37318138 | Dietary patterns in clinical subtypes of multiple sclerosis: an exploratory study |
| Q37373206 | Differential sensitivity of oligodendrocytes and motor neurons to reactive nitrogen species: implications for multiple sclerosis |
| Q48616554 | Diffuse structural and metabolic brain changes in Fabry disease |
| Q21261385 | Early B-cell Factor gene association with multiple sclerosis in the Spanish population |
| Q36260729 | Early treatment and dose optimisation BENEFIT and BEYOND. |
| Q43182727 | Early treatment: PreCISe-ly what the patient needs. |
| Q48163272 | Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event |
| Q43264955 | Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial |
| Q39944183 | Effect of noscapine and vincristine combination on demyelination and cell proliferation in vitro |
| Q35677174 | Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging |
| Q80347950 | Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis |
| Q52369778 | Erythropoietin Upregulates Brain Hemoglobin Expression and Supports Neuronal Mitochondrial Activity. |
| Q35981192 | Escalating immunotherapy of multiple sclerosis--new aspects and practical application. |
| Q44426137 | Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis |
| Q34409412 | Evolving expectations around early management of multiple sclerosis |
| Q33869433 | Focal and diffuse cortical degenerative changes in a marmoset model of multiple sclerosis |
| Q40325538 | Gait and balance deterioration over a 12-month period in multiple sclerosis patients with EDSS scores ≤ 3.0. |
| Q36260710 | Genomics and proteomics: role in the management of multiple sclerosis |
| Q37997089 | Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis |
| Q33725131 | Global N-acetylaspartate declines even in benign multiple sclerosis |
| Q31104509 | Gray and normal-appearing white matter in multiple sclerosis: an MRI perspective |
| Q46849835 | High field MR imaging and 1H-MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis: correlation between metabolic alterations and diagnostic MR imaging criteria. |
| Q34552395 | Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE. |
| Q48311479 | IFN-β1a (Rebif®) Modifies the Expression of Microfilament-Associated Cell-Cell Contacts in C6 Glioma Cells |
| Q34837632 | Identification of new therapeutic targets for prevention of CNS inflammation |
| Q26744629 | Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis |
| Q30989935 | Imaging of multiple sclerosis: role in neurotherapeutics |
| Q34213029 | Immunoexcitotoxicity as a central mechanism in chronic traumatic encephalopathy-A unifying hypothesis |
| Q45998746 | In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. |
| Q34718044 | Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. |
| Q35556109 | Interferon-β in the treatment of relapsing–remitting multiple sclerosis |
| Q31014025 | MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. |
| Q31132442 | MRI in multiple sclerosis: what's inside the toolbox? |
| Q30798662 | MRI measures of neurodegeneration in multiple sclerosis: implications for disability, disease monitoring, and treatment. |
| Q47332061 | MRI/MRS of corpus callosum in patients with clinically isolated syndrome suggestive of multiple sclerosis |
| Q37142971 | Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives. |
| Q31027957 | Magnetic resonance spectroscopy in the monitoring of multiple sclerosis |
| Q24800569 | Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy |
| Q37857752 | Managing MS in a changing treatment landscape. |
| Q36979460 | Mechanisms of neuronal damage in multiple sclerosis and its animal models: role of calcium pumps and exchangers |
| Q37800214 | Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis |
| Q48319759 | Metabolic changes in normal-appearing white matter in patients with neuromyelitis optica and multiple sclerosis: a comparative magnetic resonance spectroscopy study |
| Q46819434 | Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study |
| Q44643487 | Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy |
| Q37685038 | Metabolomic approach to human brain spectroscopy identifies associations between clinical features and the frontal lobe metabolome in multiple sclerosis. |
| Q34963755 | Microglia as liaisons between the immune and central nervous systems: functional implications for multiple sclerosis |
| Q30940050 | Multicentre proton magnetic resonance spectroscopy imaging of primary progressive multiple sclerosis |
| Q50800626 | Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-Commentary. |
| Q50800638 | Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-YES. |
| Q34027469 | Myelin loss does not lead to axonal degeneration in a long-lived model of chronic demyelination |
| Q33271816 | N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology |
| Q39310696 | N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase |
| Q33556095 | N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry |
| Q35098077 | Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli |
| Q22241472 | Neurodegeneration in multiple sclerosis: novel treatment strategies |
| Q36854014 | Neuronal Hemoglobin Expression and Its Relevance to Multiple Sclerosis Neuropathology |
| Q77486551 | Neuronal apoptosis induced by cerebrospinal fluid from multiple sclerosis patients correlates with hypointense lesions on T1 magnetic resonance imaging |
| Q37462045 | Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation |
| Q35864382 | Neurophysiological Correlates of Central Fatigue in Healthy Subjects and Multiple Sclerosis Patients before and after Treatment with Amantadine. |
| Q36993507 | Neuroprotection with glatiramer acetate: evidence from the PreCISe trial |
| Q33607732 | Neuroprotective effects of gypenosides in experimental autoimmune optic neuritis. |
| Q22242305 | New and emerging disease modifying therapies for multiple sclerosis |
| Q37428790 | New imaging techniques in the diagnosis of multiple sclerosis |
| Q33835877 | Once-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing-remitting multiple sclerosis |
| Q93104730 | Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis |
| Q48393266 | Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations |
| Q38977857 | Optical Coherence Tomography in Patients with Relapsing-Remitting Multiple Sclerosis without Optic Neuritis: A 20-Month Longitudinal Study |
| Q36435667 | Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study |
| Q26777686 | Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis |
| Q38287176 | Oxidative Stress and Neurobiology of Demyelination |
| Q34049616 | Pathogenic implications of iron accumulation in multiple sclerosis |
| Q38444650 | Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage |
| Q36965015 | Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis |
| Q36005655 | Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. |
| Q34986821 | Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects |
| Q46914516 | Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis |
| Q51971397 | Prolonged response times characterize cognitive performance in multiple sclerosis. |
| Q49089264 | Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis. |
| Q37218580 | Protecting axons in multiple sclerosis |
| Q37347220 | Proteomic strategies in multiple sclerosis and its animal models |
| Q36234355 | Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing |
| Q91707553 | Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker |
| Q44065894 | Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis |
| Q43281171 | Quantitative cervical spinal cord 3T proton MR spectroscopy in multiple sclerosis |
| Q48983171 | Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. |
| Q36907460 | Relating brain damage to brain plasticity in patients with multiple sclerosis |
| Q36028988 | Relationship between Proton Magnetic Resonance Spectroscopy of Frontoinsular Gray Matter and Neurodevelopmental Outcomes in Very Low Birth Weight Children at the Age of 4 |
| Q42363523 | Relationship between Structural and Functional Assessment of the Visual System in Mildly Disabled Relapsing-Remitting Multiple Sclerosis Patients |
| Q24652353 | Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis |
| Q34503137 | Secondary progressive multiple sclerosis: current knowledge and future challenges |
| Q46548630 | Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis |
| Q39134746 | Short-term cuprizone feeding verifies N-acetylaspartate quantification as a marker of neurodegeneration. |
| Q57911930 | Simple and complex movement-associated functional MRI changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis |
| Q46203782 | Spinal motoneurone distress during experimental allergic encephalomyelitis. |
| Q84229711 | Structural and metabolic damage in brains of patients with SPG11-related spastic paraplegia as detected by quantitative MRI |
| Q35801041 | Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate |
| Q34463760 | Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration |
| Q26795607 | Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis |
| Q48168382 | The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials |
| Q36748094 | The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis |
| Q33698702 | The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis |
| Q35557367 | The effect of smoking on the symptoms and progression of multiple sclerosis: a review |
| Q28741521 | The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials |
| Q39317856 | The neuronal metabolite NAA regulates histone H3 methylation in oligodendrocytes and myelin lipid composition |
| Q35820295 | The pathogenesis of multiple sclerosis: is it really a primary inflammatory process? |
| Q34138418 | The photopic negative response of the flash electroretinogram in multiple sclerosis |
| Q30960720 | The pros and cons of early treatment of relapsing forms of multiple sclerosis. |
| Q36474330 | The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis |
| Q45933521 | The role of axonopathy in the mechanisms of development of demyelination processes in the central and peripheral nervous system. |
| Q34240210 | The role of non-conventional MR techniques to study multiple sclerosis patients |
| Q44698424 | The unique impact of changes in normal appearing brain tissue on cognitive dysfunction in secondary progressive multiple sclerosis patients |
| Q38060795 | The use of fourth-generation optical coherence tomography in multiple sclerosis: a review |
| Q30810168 | The use of quantitative magnetic-resonance-based techniques to monitor the evolution of multiple sclerosis. |
| Q48040099 | Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis. |
| Q24681228 | Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis |
| Q38769752 | Timing of Future Remyelination Therapies and Their Potential to Stop Multiple Sclerosis Progression. |
| Q36822085 | Transcranial brain sonography findings related to neuropsychological impairment in multiple sclerosis. |
| Q33500910 | Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode |
| Q37884071 | Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability |
| Q35805861 | Treatment optimization in multiple sclerosis |
| Q30768212 | Twelve-year monitoring of a patient with megalencephalic leukoencephalopathy with subcortical cysts. |
| Q26991740 | Viruses and neurodegeneration |
| Q35374052 | When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults? |
| Q37972980 | White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis |
| Q43186466 | Zellweger Spectrum Disorder with Mild Phenotype Caused by PEX2 Gene Mutations |
| Q84066783 | [Magnetic resonance imaging of central nervous system inflammation] |
| Q79836642 | [Multiple sclerosis. An update with practical guidelines for ophthalmologists] |
Search more.